Alexander Dahmani, Director, Business Development, Adaptive Biotechnologies, was Chief Executive Officer of QuiO until 2021, a company which he founded in 2014 while pursuing a PhD in Microbiology and Immunology at Columbia University (New York, NY, US).

At Columbia, his research focused on human T cell activity using an advanced humanised mouse model. During his PhD he also worked for Columbia Technology Ventures, where he helped review and commercialise new technologies invented on campus, including algorithms, sensors, medical devices and therapeutic molecules.

Prior to Columbia, he worked for Heat Biologics (Nasdaq: HTBX), a biotech start-up commercialising a novel cellular immunotherapy for multiple cancer indications. Mr Dahmani earned a BS in Genetics with a minor in Business from the University of Wisconsin (Madison, WI, US).

More contributions